Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02551874 · ClinicalTrials.gov registry record · Phase 3
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 650
- Enrollment target
- 20
- Study locations
NCT02551874: Completed Phase 3 study of Type 2 Diabetes Mellitus, sponsored by AstraZeneca.
NCT02551874 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by AstraZeneca. The registered enrollment target is 650 participants, below the 2,955-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02551874, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 650 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to metformin with or without sulfonylurea, to subjects receiving insulin glargine, in addition to metformin with or without sulfonylurea, over a treatment period of 52 weeks.
Primary Outcome
To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin with or without SU is noninferior (noninferiority margin of 0.3%) to titrated insulin glargine plus metformin with or without SU after 24 weeks of open-label treatment.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Glargine insulin
- DRUG Saxagliptin, Onglyza
- DRUG Dapagliflozin, Farxiga
Study Locations (20)
Texas
- Research Site - Houston
- Research Site - Mesquite
- Research Site - San Antonio
- Research Site - San Antonio
Florida
- Research Site - Miami
- Research Site - Miami
- Research Site - St. Petersburg
California
- Research Site - Anaheim
- Research Site - Los Angeles
Tennessee
- Research Site - Bristol
- Research Site - Kingsport
Georgia
- Research Site - Norcross
Illinois
- Research Site - Chicago
Kentucky
- Research Site - Lexington
Massachusetts
- Research Site - Quincy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2015-10-20 |
| Est. Completion | 2017-11-10 |
| Phase | Phase 3 |
What the finished NCT02551874 record still lists
NCT02551874 is an interventional study that assigns participants to a tested intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, below the 2,955-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Metformin is the first listed.
NCT02551874 names 20 study sites across 13 states, led by Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT02551874 about?
NCT02551874 is a clinical study titled "A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin". This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to metformin with or without sulfonylurea, to subjects receiving insulin glargine,...
What is the current status of trial NCT02551874?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 650 participants. The study started on 2015-10-20. Estimated completion is 2017-11-10.
What conditions does trial NCT02551874 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT02551874?
The interventions under investigation include: Metformin (DRUG), Glargine insulin (DRUG), Saxagliptin, Onglyza (DRUG), Dapagliflozin, Farxiga (DRUG).
Who is sponsoring clinical trial NCT02551874?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02551874 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02551874's enrollment target sits among peer trials
650 17th of 130 higher than 114 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
RECRUITING · Phase 3
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
COMPLETED · Phase 3
-
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
-
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI